Literature DB >> 25436794

Refining the toxicity profile of crizotinib.

Benjamin Solomon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25436794     DOI： 10.1097/JTO.0000000000000375

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

Review 1.  New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

Authors:  Laird Cameron; Benjamin Solomon
Journal:  Curr Treat Options Oncol       Date:  2015-10

Review 2.  Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.

Authors:  Laird Cameron; Benjamin Solomon
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

3.  Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature.

Authors:  Lei Deng; Janaki Sharma; Elizabeth Ravera; Balazs Halmos; Haiying Cheng
Journal:  Lung Cancer (Auckl)       Date:  2018-09-06

Review 4.  Second- and third-generation ALK inhibitors for non-small cell lung cancer.

Authors:  Jingjing Wu; John Savooji; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-03-08       Impact factor: 17.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.